FCR Expression of interest

 
50% of survey complete.
Please discuss this with your MDM team, ensuring that you answer each question with a single response for your institution.
Please answer the questions below about this study, a  prospective longitudinal cohort study to address Fear of Cancer Recurrence (FCR) in NSCLC.

Brief summary:
Background:  Despite surgery, the recurrence rates of NSCLC range from 30% to 75%. Fear of cancer recurrence (FCR) is a debilitating problem and is an unmet need in lung cancer survivors. Little is known about FCR prevalence and its effects in lung cancer and by identifying this, an intervention can be designed in future to reduce the level of FCR in these patients.
 
Aim:  To determine the frequency, severity, time course, nature, predictors, and consequences of FCR after surgery with curative intent for NSCLC.

Objectives:  To determine the:
Primary
1.      Prevalence of FCR using at 6 months after surgery
Secondary
2.      FCR prevalence pattern over time
3.      FCR nature using qualitative interviews
4.      FCR between clinic visits and at the time of scans
5.      FCR potential predictors
6.      Associations between FCR and anxiety, depression, other aspects of health related quality of life
Tertiary correlatives
Associations between FCR with frequency of medical visits and/or scans, and use of complementary medicine - patient diary

Target population:  Adult patients with early stage NSCLC (stages 1-3A) who have had surgery with curative intent within 2 months of registration.
 
Study interventions: 
1. 5 questionnaires (FCRI-SS, HADS, STAI, EORTC QLQ-30 and QLQ LC-13) in 15 minutes
- Baseline, 3, 6, 12 and 18 months post surgery
2. Qualitative interviews in selected patients

Estimated recruitment timelines:
1. First patient in: 2nd quarter 2018
2. Approximate number of months for recruitment: 24 months
3. Approximate number of patients: 200

Question Title

* 1. Investigator Details

Question Title

* 2. Do you have a cardiothoracic surgeon (CTS) who performs lung cancer at your site?

Question Title

* 3. How many resected Stage I-IIIA NSCLC patients do you see at your site per year?

Question Title

* 4. Are all patients who had resected NSCLC discussed at your multidisciplinary meeting?

Question Title

* 5. How many resected Stage I-IIIA NSCLC patients do you think you would recruit to this study per year?

Question Title

* 6. Do you have a lung/ thoracic cancer-specific nurse/ care coordinator at your site?

Question Title

* 7. What is your level of enthusiasm for this trial?

Question Title

* 8. Does your institution wish to participate in this trial?

T